This secondary analysis (n=79 of n=233) of a Phase II randomised trial examined whether therapeutic alliance or the psychedelic experience itself better predicted antidepressant outcomes in people with treatment-resistant depression (TRD) receiving psilocybin (25 mg), finding that measures of the psychedelic experience were more strongly associated with reduced depression scores than pre-dosing therapeutic alliance, though alliance did appear to modestly facilitate the quality of the psychedelic experience.
- Published
- Journal
- Journal of Affective Disorders
- Authors
- Goodwin, G. M., Aaronson, S. T., Alvarez, O., Carhart-Harris, R., Croal, M., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Kirlic, N., Licht, R. W., Marwood, L., Nowakowska, A., Páleníček, T., Repantis, D., Schoevers, R. A., Simmons, H., Soares, J. C., Somers, M., Tsai, J., Wahba, M., Williams, E., Young, A. H., Young, M. B., Zisook, S., Malievskaia, E.